Sign in or create an account to add this stock to your watchlist.
About Spero Therapeutics (NASDAQ:SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting. The company also develops SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; SPR720, an oral antibiotic, which is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPRO
CUSIPN/A
Phone857-242-1600
Debt
Debt-to-Equity RatioN/A
Current Ratio13.68
Quick Ratio13.68
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.98 million
Price / Sales75.60
Cash FlowN/A
Price / CashN/A
Book Value$5.21 per share
Price / Book2.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees35
Outstanding Shares14,380,000
Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions
What is Spero Therapeutics' stock symbol?
Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."
How were Spero Therapeutics' earnings last quarter?
Spero Therapeutics (NASDAQ:SPRO) issued its quarterly earnings data on Thursday, May, 10th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($1.20) by $0.46. The firm earned $1.15 million during the quarter, compared to analyst estimates of $0.20 million. View Spero Therapeutics' Earnings History.
What price target have analysts set for SPRO?
6 Wall Street analysts have issued twelve-month target prices for Spero Therapeutics' shares. Their forecasts range from $26.00 to $30.00. On average, they anticipate Spero Therapeutics' share price to reach $27.75 in the next twelve months. View Analyst Ratings for Spero Therapeutics.
What are Wall Street analysts saying about Spero Therapeutics stock?
Here are some recent quotes from research analysts about Spero Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "We met with Spero’s senior management today. In attendance were: Ankit Mahadevia, MD (CEO), Joel Sendek (CFO), Cristina Larkin (COO), and Sharon Klahre (IR). We come away from the meeting positive on the stock and reiterate our Overweight rating as well as our $27 PT ahead of what we expect to be several positive data readouts this year." (4/30/2018)
- 2. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/21/2018)
Who are some of Spero Therapeutics' key competitors?
Some companies that are related to Spero Therapeutics include Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Prothena (PRTA), Aclaris Therapeutics (ACRS), Akebia Therapeutics (AKBA), AC Immune (ACIU), CannTrust (CNTTF), Kura Oncology (KURA), Evolus (EOLS), Progenics Pharmaceuticals (PGNX), TIGENIX/S (TIG), Achaogen (AKAO), Insys Therapeutics (INSY), Evelo Biosciences (EVLO) and Cara Therapeutics (CARA).
Who are Spero Therapeutics' key executives?
Spero Therapeutics' management team includes the folowing people:
- Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 37)
- Dr. Thomas R. Parr Jr., Ph.D., Chief Scientific Officer (Age 64)
- Mr. Joel D. Sendek, CFO & Treasurer (Age 51)
- Ms. Cristina Larkin, Chief Operating Officer (Age 48)
- Ms. Sharon Klahre, Director of Investor Relations
When did Spero Therapeutics IPO?
(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.
When did the company's lock-up period expire?
Spero Therapeutics' lock-up period expired on Tuesday, May 1st. Spero Therapeutics had issued 5,500,000 shares in its IPO on November 2nd. The total size of the offering was $77,000,000 based on an initial share price of $14.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Spero Therapeutics been receiving favorable news coverage?
News articles about SPRO stock have trended somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spero Therapeutics earned a media sentiment score of 0.03 on Accern's scale. They also assigned press coverage about the company an impact score of 46.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Spero Therapeutics' major shareholders?
Spero Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (7.30%), JPMorgan Chase & Co. (1.78%), BlackRock Inc. (1.76%), DAFNA Capital Management LLC (0.21%) and Millennium Management LLC (0.08%). Company insiders that own Spero Therapeutics stock include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Institutional Ownership Trends for Spero Therapeutics.
Which major investors are buying Spero Therapeutics stock?
SPRO stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., DAFNA Capital Management LLC, BVF Inc. IL, BlackRock Inc. and Millennium Management LLC. Company insiders that have bought Spero Therapeutics stock in the last two years include Casper Breum, Cristina Larkin, Joel Sendek and Plc Glaxosmithkline. View Insider Buying and Selling for Spero Therapeutics.
How do I buy shares of Spero Therapeutics?
Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spero Therapeutics' stock price today?
One share of SPRO stock can currently be purchased for approximately $10.41.
How big of a company is Spero Therapeutics?
Spero Therapeutics has a market capitalization of $152.12 million and generates $1.98 million in revenue each year. The company earns $-38,740,000.00 in net income (profit) each year or ($17.82) on an earnings per share basis. Spero Therapeutics employs 35 workers across the globe.
How can I contact Spero Therapeutics?
Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected]
MarketBeat Community Rating for Spero Therapeutics (SPRO)
MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote "Outperform" if you believe SPRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spero Therapeutics (NASDAQ:SPRO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Spero Therapeutics in the last 12 months. Their average twelve-month price target is $27.75, suggesting that the stock has a possible upside of 166.57%. The high price target for SPRO is $30.00 and the low price target for SPRO is $26.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.80 | 2.80 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.75 | $27.6667 | $27.6667 | $28.00 |
| Price Target Upside: | 166.57% upside | 83.83% upside | 129.03% upside | 102.02% upside |
Spero Therapeutics (NASDAQ:SPRO) Consensus Price Target History
Spero Therapeutics (NASDAQ:SPRO) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Spero Therapeutics (NASDAQ:SPRO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 8/7/2015 | quarterly | $0.0150 | 2.97% | 9/16/2015 | 9/18/2015 | 10/7/2015 |
| 5/6/2015 | quarterly | $0.0150 | 3.49% | 6/17/2015 | 6/19/2015 | 7/7/2015 |
| 3/6/2015 | quarterly | $0.0150 | 4.44% | 3/18/2015 | 3/20/2015 | 4/7/2015 |
| 11/5/2014 | quarterly | $0.0150 | 3.59% | 12/17/2014 | 12/19/2014 | 1/6/2015 |
| 8/11/2014 | quarterly | $0.0150 | 3.23% | 9/17/2014 | 9/19/2014 | 10/7/2014 |
| 5/9/2014 | quarterly | $0.0150 | 2.38% | 6/18/2014 | 6/20/2014 | 7/7/2014 |
| 3/6/2014 | quarterly | $0.0150 | 2.4% | 3/19/2014 | 3/21/2014 | 4/7/2014 |
| 11/8/2013 | quarterly | $0.0150 | 2.79% | 12/17/2013 | 12/19/2013 | 1/6/2014 |
| 8/7/2013 | quarterly | $0.0150 | 3.68% | 9/17/2013 | 9/19/2013 | 10/7/2013 |
| 5/8/2013 | quarterly | $0.0150 | 3.9% | 6/12/2013 | 6/14/2013 | 7/5/2013 |
| 3/8/2013 | quarterly | $0.0150 | 3.95% | 3/20/2013 | 3/22/2013 | 4/5/2013 |
(Data available from 1/1/2013 forward)
Spero Therapeutics (NASDAQ SPRO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 26.90%
Institutional Ownership Percentage: 45.87%
Spero Therapeutics (NASDAQ SPRO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/6/2017 | Casper Breum | Director | Buy | 214,285 | $14.00 | $2,999,990.00 | |  |
| 11/6/2017 | Cristina Larkin | COO | Buy | 1,500 | $14.00 | $21,000.00 | | |
| 11/6/2017 | Joel Sendek | CFO | Buy | 5,000 | $14.00 | $70,000.00 | | |
| 11/6/2017 | Plc Glaxosmithkline | Major Shareholder | Buy | 428,571 | $14.00 | $5,999,994.00 | | |
| 3/11/2013 | Allen S Greene | CEO | Buy | 15,000 | $1.53 | $22,950.00 | | |
| 12/28/2012 | Zohar Ben-Dov | Major Shareholder | Buy | 22,693 | $1.19 | $27,004.67 | | |
| 12/24/2012 | Jack Fingerhut | President | Buy | 2,000 | $2.40 | $4,800.00 | | |
| 9/5/2012 | John J Gorman | Director | Buy | 4,600 | $1.90 | $8,740.00 | | |
| 8/30/2012 | Allen S Greene | CEO | Buy | 5,000 | $1.82 | $9,100.00 | | |
(Data available from 1/1/2013 forward)
Spero Therapeutics (NASDAQ SPRO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | FY2018 Earnings Forecast for Spero Therapeutics Issued By Cantor Fitzgerald (SPRO)
www.americanbankingnews.com - May 24 at 8:34 AM |
| Spero Therapeutics (SPRO) Given a $30.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 23 at 6:30 PM |
| Spero Therapeutics (SPRO) PT Set at $27.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 11:54 AM |
 | Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
finance.yahoo.com - May 23 at 8:53 AM |
| Brokerages Anticipate Spero Therapeutics (SPRO) Will Post Quarterly Sales of $620,000.00
www.americanbankingnews.com - May 19 at 2:34 AM |
| Zacks: Analysts Expect Spero Therapeutics (SPRO) Will Post Earnings of -$0.88 Per Share
www.americanbankingnews.com - May 17 at 5:31 PM |
| Q2 2018 EPS Estimates for Spero Therapeutics (SPRO) Boosted by Oppenheimer
www.americanbankingnews.com - May 16 at 7:32 AM |
| Spero Therapeutics (SPRO) Given a $30.00 Price Target at Oppenheimer
www.americanbankingnews.com - May 14 at 12:42 PM |
| Spero Therapeutics (SPRO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 1:39 AM |
| Spero Therapeutics (SPRO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 2:25 PM |
| Spero Therapeutics (SPRO) Now Covered by HC Wainwright
www.americanbankingnews.com - May 11 at 5:49 PM |
| Cantor Fitzgerald Analysts Give Spero Therapeutics (SPRO) a $27.00 Price Target
www.americanbankingnews.com - May 11 at 3:56 PM |
 | Spero Therapeutics beats by $0.46, beats on revenue
seekingalpha.com - May 11 at 9:45 AM |
| Spero Therapeutics Announces First Quarter 2018 Financial Results and Pipeline Update
finance.yahoo.com - May 10 at 5:01 PM |
| Spero Therapeutics (SPRO) PT Set at $30.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 10:31 PM |
| Spero Therapeutics (SPRO) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM |
 | Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
feeds.benzinga.com - May 1 at 9:55 AM |
| Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May
finance.yahoo.com - May 1 at 9:07 AM |
| Spero Therapeutics' (SPRO) Buy Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 4:12 PM |
| Wired News – CDC Publishes Dynavax’s HEPLISAV-B(R) ACIP Recommendations in Morbidity and Mortality Weekly Report
finance.yahoo.com - April 25 at 9:05 AM |
| Spero Therapeutics' (SPRO) Lock-Up Period Will Expire on May 1st
www.americanbankingnews.com - April 24 at 1:18 AM |
| Spero Therapeutics Inc (SPRO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM |
 | Eight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerability
globenewswire.com - April 16 at 8:58 AM |
| Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
finance.yahoo.com - April 12 at 9:52 AM |
| Spero Therapeutics (SPRO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:48 PM |
| These Alphabet-Backed Biotech Startups Went Public In 1Q18
finance.yahoo.com - April 6 at 9:23 AM |
| Q1 2018 EPS Estimates for Spero Therapeutics Inc Increased by Oppenheimer (SPRO)
www.americanbankingnews.com - April 6 at 7:58 AM |
| FY2018 EPS Estimates for Spero Therapeutics Inc Reduced by Analyst (SPRO)
www.americanbankingnews.com - April 6 at 7:24 AM |
| Analysts Set Expectations for Spero Therapeutics Inc's FY2022 Earnings (SPRO)
www.americanbankingnews.com - April 5 at 8:46 AM |
| Oppenheimer Analysts Give Spero Therapeutics (SPRO) a $30.00 Price Target
www.americanbankingnews.com - April 4 at 8:04 AM |
| Spero Therapeutics misses by $0.24, beats on revenue
seekingalpha.com - April 3 at 9:19 AM |
| Spero Therapeutics (SPRO) Announces Earnings Results, Beats Expectations By $0.18 EPS
www.americanbankingnews.com - April 3 at 7:46 AM |
| Spero Therapeutics (SPRO) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - April 2 at 9:11 PM |
| Spero Therapeutics (SPRO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:47 PM |
| Where Spero Therapeutics Inc’s (NASDAQ:SPRO) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 29 at 4:47 PM |
| Zacks: Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 29 at 10:40 AM |
| -$1.56 EPS Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - March 27 at 5:53 AM |
| Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:44 AM |
| Oppenheimer Reaffirms Buy Rating for Spero Therapeutics (SPRO)
www.americanbankingnews.com - March 21 at 7:48 PM |
| Brokerages Anticipate Spero Therapeutics Inc (SPRO) Will Post Quarterly Sales of $400,000.00
www.americanbankingnews.com - March 11 at 1:56 AM |
| VHCP Management II LLC Takes Position in Spero Therapeutics Inc (SPRO)
www.americanbankingnews.com - March 6 at 10:31 AM |
| AWM Investment Company Inc. Invests $4.11 Million in Spero Therapeutics Inc (SPRO) Stock
www.americanbankingnews.com - March 6 at 4:45 AM |
| Spero Therapeutics to Present at March Investor Conferences
finance.yahoo.com - March 1 at 8:53 AM |
| Spero Therapeutics Inc (SPRO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 1:52 AM |
| $400,000.00 in Sales Expected for Spero Therapeutics Inc (SPRO) This Quarter
www.americanbankingnews.com - February 23 at 1:28 PM |
| Spero Therapeutics (SPRO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 21 at 1:42 PM |
| Analysts Anticipate Spero Therapeutics Inc (SPRO) Will Announce Earnings of -$1.56 Per Share
www.americanbankingnews.com - February 21 at 10:31 AM |
| Head-To-Head Survey: Aptevo Therapeutics (APVO) versus Spero Therapeutics (SPRO)
www.americanbankingnews.com - February 21 at 1:30 AM |
| Spero Therapeutics (SPRO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 14 at 12:32 PM |
| Spero Therapeutics Inc (SPRO) Forecasted to Post FY2018 Earnings of ($3.69) Per Share
www.americanbankingnews.com - February 14 at 10:46 AM |
Spero Therapeutics (NASDAQ:SPRO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spero Therapeutics (NASDAQ:SPRO) Income Statement, Balance Sheet and Cash Flow Statement
Spero Therapeutics (NASDAQ SPRO) Stock Chart for Saturday, May, 26, 2018
Loading chart…
